We discuss the molecular mechanisms linking DPP3 to cardiovascular and renal regulation, summarize experimental and clinical evidence of its diagnostic and prognostic significance in heart failure, acute coronary syndromes, cardiogenic and septic shock, and explore emerging data on antibody-mediated inhibition as a potential therapeutic approach. This evidence concerns the gene DPP3 and acute coronary syndrome.